Edwards Lifesciences Longtime Chair To Retire
By Ben Glickman
Edwards Lifesciences said Tuesday that chair Michael Mussallem planned to retire about a year after stepping down as chief executive.
The Irvine, Calif.-based company said in a regulatory filing that Mussallem, who served as CEO of Edwards from 2000 to 2023, is expected to be succeeded as chair by Nicholas Valeriani, an independent director.
Mussallem retired as CEO at the 2023 annual meeting, transitioning into the non-executive chair role. He was succeeded in the CEO role by Bernard Zovighian.
The company's annual meeting is scheduled for May 7.
Edwards said in the filing that board member Martha Marsh had reached the retirement age outlined in the company's governance guidelines.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
March 26, 2024 16:42 ET (20:42 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Markets Brief: Tech Stocks Lead Ahead of Nvidia Earnings
-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing